<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00081237</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-16033</org_study_id>
    <secondary_id>EORTC-16033</secondary_id>
    <secondary_id>OSI-EORTC-16033</secondary_id>
    <nct_id>NCT00081237</nct_id>
  </id_info>
  <brief_title>OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer</brief_title>
  <official_title>A Phase I Study of OSI-7904L In Combination With Oxaliplatin In Patients With Advanced Colo-Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: OSI-7904L may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      their growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Combining OSI-7904L with oxaliplatin&#xD;
      may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of OSI-7904L and&#xD;
      oxaliplatin in treating patients with refractory or recurrent advanced colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the dose-limiting toxicity of OSI-7904L and oxaliplatin in patients with&#xD;
           refractory or recurrent advanced colorectal cancer.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of this regimen in these patients.&#xD;
&#xD;
        -  Determine a safe dose for this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the safety profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the antitumor activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, multicenter, open-label, dose-escalation study.&#xD;
&#xD;
      Patients receive oxaliplatin IV over 2 hours followed by OSI-7904L IV over 30 minutes on day&#xD;
      1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of OSI-7904L and oxaliplatin until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 6 patients experience dose-limiting toxicity. A maximum of 12 patients receive&#xD;
      treatment at the MTD.&#xD;
&#xD;
      Patients are followed every 8 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose and recommended dose for future trials as measured by CTC v3.0</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile as measured by CTC v3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response as measured by RECIST every 6 weeks (2 courses)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics as measured by drug concentration in the blood during course 1</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression as measured by Kaplan Meier and RECIST every 6 weeks during treatment and then every 8 weeks</measure>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OSI-7904L</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed colorectal cancer&#xD;
&#xD;
               -  Radiologic evidence of advanced disease&#xD;
&#xD;
          -  At least 1 measurable lesion at least 20 mm OR at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Indicator lesions in a previously irradiated field are allowed provided the&#xD;
                  irradiated lesion has clearly progressed OR a new lesion has developed in the&#xD;
                  irradiated field&#xD;
&#xD;
          -  Failed 1, and only 1, line of prior chemotherapy for advanced/metastatic disease&#xD;
&#xD;
               -  Disease progression during chemotherapy OR within 6 months after completion of&#xD;
                  treatment&#xD;
&#xD;
          -  No symptomatic brain metastases meeting any of the following criteria:&#xD;
&#xD;
               -  Unstable&#xD;
&#xD;
               -  Inadequately controlled with fixed-dose oral steroids&#xD;
&#xD;
               -  Potentially life-threatening&#xD;
&#xD;
               -  Required radiotherapy with the past 28 days&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases&#xD;
             are present)&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
          -  No hepatitis&#xD;
&#xD;
          -  No cirrhosis&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No preexisting neuropathy ≥ grade 2&#xD;
&#xD;
          -  No active or uncontrolled infection&#xD;
&#xD;
          -  No other serious illness or medical condition&#xD;
&#xD;
          -  No chronic alcohol abuse&#xD;
&#xD;
          -  No known hypersensitivity to systemic liposomal formulations or compounds chemically&#xD;
             related to OSI-7904L or oxaliplatin&#xD;
&#xD;
          -  No prior psychiatric or neurologic condition that would preclude study compliance or&#xD;
             giving informed consent&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 21 days since prior immunotherapy&#xD;
&#xD;
          -  At least 21 days since prior monoclonal antibody therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 21 days since prior chemotherapy and recovered*&#xD;
&#xD;
          -  No prior oxaliplatin NOTE: *Alopecia allowed&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 21 days since prior hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 21 days since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of bone marrow reserve&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 21 days since prior tyrosine kinase inhibitor therapy&#xD;
&#xD;
          -  More than 21 days since prior investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Schoffski, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital N.H.S. Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Clamp AR, Schöffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS, Debois M, Lacombe D, Twelves C, Chick J, Jayson GC; EORTC New Drug Development Group. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008 Apr;61(4):579-85. Epub 2007 May 23.</citation>
    <PMID>17520255</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

